345 related articles for article (PubMed ID: 28374482)
1. Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: Results from a Japanese clinical trial.
Kitaoka T; Tajima T; Nagasaki K; Kikuchi T; Yamamoto K; Michigami T; Okada S; Fujiwara I; Kokaji M; Mochizuki H; Ogata T; Tatebayashi K; Watanabe A; Yatsuga S; Kubota T; Ozono K
Clin Endocrinol (Oxf); 2017 Jul; 87(1):10-19. PubMed ID: 28374482
[TBL] [Abstract][Full Text] [Related]
2. Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia.
Whyte MP; Rockman-Greenberg C; Ozono K; Riese R; Moseley S; Melian A; Thompson DD; Bishop N; Hofmann C
J Clin Endocrinol Metab; 2016 Jan; 101(1):334-42. PubMed ID: 26529632
[TBL] [Abstract][Full Text] [Related]
3. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial.
Whyte MP; Simmons JH; Moseley S; Fujita KP; Bishop N; Salman NJ; Taylor J; Phillips D; McGinn M; McAlister WH
Lancet Diabetes Endocrinol; 2019 Feb; 7(2):93-105. PubMed ID: 30558909
[TBL] [Abstract][Full Text] [Related]
4. Asfotase Alfa in Perinatal/Infantile-Onset and Juvenile-Onset Hypophosphatasia: A Guide to Its Use in the USA.
Scott LJ
BioDrugs; 2016 Feb; 30(1):41-8. PubMed ID: 26832358
[TBL] [Abstract][Full Text] [Related]
5. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Del Angel G; Zhou S; Rush ET
Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268
[TBL] [Abstract][Full Text] [Related]
6. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP
Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
[TBL] [Abstract][Full Text] [Related]
7. Asfotase alfa therapy for children with hypophosphatasia.
Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C
JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270
[No Abstract] [Full Text] [Related]
8. Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.
Scott LJ
Drugs; 2016 Feb; 76(2):255-62. PubMed ID: 26744272
[TBL] [Abstract][Full Text] [Related]
9. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia.
Hofmann C; Seefried L; Jakob F
Drugs Today (Barc); 2016 May; 52(5):271-85. PubMed ID: 27376160
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study.
Hofmann CE; Harmatz P; Vockley J; Högler W; Nakayama H; Bishop N; Martos-Moreno GÁ; Moseley S; Fujita KP; Liese J; Rockman-Greenberg C;
J Clin Endocrinol Metab; 2019 Jul; 104(7):2735-2747. PubMed ID: 30811537
[TBL] [Abstract][Full Text] [Related]
11. Asfotase alfa (Strensiq) for hypophosphatasia.
Med Lett Drugs Ther; 2016 Jul; 58(1499):e96. PubMed ID: 27403786
[No Abstract] [Full Text] [Related]
12. A Japanese single-center experience of the efficacy and safety of asfotase alfa in pediatric-onset hypophosphatasia.
Sugiyama Y; Watanabe T; Tajika M; Matsuhashi T; Shimura M; Fushimi T; Ichimoto K; Matsunaga A; Ebihara T; Tsuruoka T; Akiyama T; Murayama K
Orphanet J Rare Dis; 2022 Feb; 17(1):78. PubMed ID: 35197081
[TBL] [Abstract][Full Text] [Related]
13. Lethal hypophosphatasia successfully treated with enzyme replacement from day 1 after birth.
Okazaki Y; Kitajima H; Mochizuki N; Kitaoka T; Michigami T; Ozono K
Eur J Pediatr; 2016 Mar; 175(3):433-7. PubMed ID: 26459154
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphatasia: presentation and response to asfotase alfa.
Alsarraf F; Ali DS; Almonaei K; Al-Alwani H; Khan AA; Brandi ML
Osteoporos Int; 2024 Apr; 35(4):717-725. PubMed ID: 37993691
[TBL] [Abstract][Full Text] [Related]
15. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa.
Kishnani PS; Rush ET; Arundel P; Bishop N; Dahir K; Fraser W; Harmatz P; Linglart A; Munns CF; Nunes ME; Saal HM; Seefried L; Ozono K
Mol Genet Metab; 2017 Sep; 122(1-2):4-17. PubMed ID: 28888853
[TBL] [Abstract][Full Text] [Related]
16. Hypophosphatasia: From Diagnosis to Treatment.
Simon S; Resch H; Klaushofer K; Roschger P; Zwerina J; Kocijan R
Curr Rheumatol Rep; 2018 Sep; 20(11):69. PubMed ID: 30203264
[TBL] [Abstract][Full Text] [Related]
17. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia.
Bowden SA; Adler BH
Osteoporos Int; 2018 Feb; 29(2):511-515. PubMed ID: 29046930
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Efficacy of Reduced Doses of Asfotase Alfa Replacement Therapy in an Infant With Hypophosphatasia Who Lacked Severe Clinical Symptoms.
Fujisawa Y; Kitaoka T; Ono H; Nakashima S; Ozono K; Ogata T
Front Endocrinol (Lausanne); 2020; 11():590455. PubMed ID: 33391183
[TBL] [Abstract][Full Text] [Related]
19. Spurious testosterone laboratory results in a patient taking synthetic alkaline phosphatase (asfotase alfa).
Sofronescu AG; Ross M; Rush E; Goldner W
Clin Biochem; 2018 Aug; 58():118-121. PubMed ID: 29709501
[TBL] [Abstract][Full Text] [Related]
20. Enzyme Replacement Therapy in Hypophosphatasia.
Uçaktürk SA; Elmaogullari S; Ünal S; Gönülal D; Mengen E
J Coll Physicians Surg Pak; 2018 Sep; 28(9):S198-S200. PubMed ID: 30173697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
